ArticleJournal of ovarian research2026
C-Phycocyanin ameliorates ovarian hyperstimulation syndrome by mitigating inflammation and enhances fertility in an OHSS mouse model.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundOvarian hyperstimulation syndrome (OHSS) is a serious complication of assisted reproductive technology, particularly during gonadotropin-induced superovulation in in vitro fertilization and embryo transfer. Driven by elevated vascular endothelial growth factor (VEGF) levels and inflammation, OHSS increases vascular permeability and impairs reproductive capability. Given the lack of specific treatments, novel therapeutic strategies are urgently needed. C-Phycocyanin (PC), an extract from Spirulina, is known for its anti-inflammatory, antioxidant, anti-cancer, and immune-boosting properties. We established an OHSS mouse model and administered PC via gavage for 45 consecutive days to evaluate its effectiveness as a treatment for OHSS.
methodsFemale mice were randomly divided into three groups: control, OHSS, and OHSS treated with PC. The protective effects of PC against OHSS were assessed at systemic, ovarian, and molecular levels.
resultsPC ameliorated the typical pathological features of OHSS in the murine model. Specifically, PC treatment significantly reduced body weight gain, ovarian weight, and vascular permeability, while restoring serum anti-Müllerian hormone and estradiol levels to near-normal ranges. PC restored aspartate aminotransferase and creatinine levels and decreased white blood cell count, and ovarian inflammation (Vegf, TNF-α, IL-6, IL-8 mRNA levels). Secondary and antral follicle counts, oocyte numbers, and polar body extrusion increased. Reactive oxygen species, mitochondrial aggregation, and apoptosis reduced; embryo development and litter size improved. No adverse offspring effects were observed.
conclusionPC mitigates ovarian hyperstimulation syndrome by reducing VEGF-mediated vascular permeability and ovarian inflammation, improving ovarian reserve, oocyte quality, and reproductive outcomes in mice, supporting its potential clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.